Recommend Technology Appraisals

Service Notification Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause

Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over

Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma

Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599)

Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881)

Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myelom

Service Notification Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy

Service Notification Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over 

Service Notification Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer

Service Notification Targeted-release budesonide for treating primary IgA nephropathy (review of TA937)

Service Notification Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer

Service Notification Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer (review of TA673)

Service Notification Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer (1)

Service Notification Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer

Service Notification Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy (review of TA212 and partial review of TA118 & TA242)

Service Notification Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma

Service Notification Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment

Service Notification Obinutuzumab with mycophenolate mofetil for treating lupus nephritis

Service Notification Dupilumab for treating severe chronic rhinosinusitis with nasal polyps